GLSI Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About GLSI Interactive Breakdown Better Bets vs. GLSI Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Greenwich LifeSciences (GLSI)

    Market Price (8/19/2026): $17.38 | Market Cap: $254.1 MilSector: Health Care | Industry: Biotechnology

    Greenwich LifeSciences (GLSI)

    Market Price (8/19/2026): $17.38
    Market Cap: $254.1 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -15%, 3Y Excs Rtn is -8.9%

    Meaningful short interest
    Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -22 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%

    Key risks
    GLSI key risks include [1] its total dependence on the successful clinical trial outcome and regulatory approval of its single product candidate, Show more.

    0 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
    1 Weak multi-year price returns
    2Y Excs Rtn is -15%, 3Y Excs Rtn is -8.9%
    2 Meaningful short interest
    Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
    3 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    4 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -22 Mil
    5 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -13%
    6 Key risks
    GLSI key risks include [1] its total dependence on the successful clinical trial outcome and regulatory approval of its single product candidate, Show more.

    GLSI in ETFs

    Weight = GLSI's share of each fund

    VTI0.00%
    IWM0.00%
    IWO0.01%
    VTWO0.00%

    Valuation & Metrics

    FYE: 12/31GLSI [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$0.0 Mil—
    FY 2027 Sales$8.8 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth—13.7%
    EARNINGS
    LTM Net Income (GAAP) [3]$-21.7 Mil—
    FY 2026 Net Income (Non-GAAP)$-18.7 Mil—
    FY 2027 Net Income (Non-GAAP)$-15.8 Mil—
    FY 2027 Net Income Growth—19.4%
    FY 2026 EPS (Non-GAAP)$-1.39—
    FY 2027 EPS (Non-GAAP)$-1.17—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S—1.7
    FY 2027 P/S29.0—
    FY 2026 P/E—7.6
    FY 2027 P/E——

    [1] GLSI forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 8/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Number of Countries in Flamingo-01 Clinical Trial1110092025Link
    Number of Active Clinical Sites in Flamingo-01 Trial1174032025Link
    Planned Patient Enrollment in Flamingo-01 Trial (Double-Blinded Arms)approximately 5001222025Link
    Planned Patient Enrollment in Flamingo-01 Trial (Open-Label Arm)up to 2501222025Link
    FDA Regulatory DesignationFast Track9102025Link
    Potential Patent Life ExtensionBeyond 20403032022Link
    Commercially Manufactured Doses of GP2approximately 200,0001222025Link
    Total Patients Treated with GLSI-100 Across All Clinical Trials1464192022Link

    Price Chart

    null
    Upcoming
    11/13/2026Earnings ReleaseRev: -
    EPS: -

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 8/12/2026

    Greenwich LifeSciences (GLSI) stock has lost about 25% since 4/30/2026 because of the following key factors:

    1. Increased Net Loss and Going Concern Risk. For the six months ending June 30, 2026 (fiscal Q2 2026), Greenwich LifeSciences reported a net loss of $9.6 million, an increase from $6.5 million in the prior-year period. This rise in losses, driven by higher research and development and stock-based compensation expenses, led management to express "substantial doubt about the ability to continue as a going concern within one year" due to recurring losses and negative operating cash flows.

    2. Share Dilution from At-The-Market Offerings. The company continued to rely on At-The-Market (ATM) equity offerings to fund its operations, leading to share dilution. During the first half of fiscal year 2026 (ending June 30, 2026), Greenwich LifeSciences issued 379,762 shares through ATM offerings, generating net proceeds of $9.3 million.

    Show more
    Updated on 8/12/2026

    Greenwich LifeSciences (GLSI) stock has lost about 25% since 4/30/2026 because of the following key factors:

    1. Increased Net Loss and Going Concern Risk. For the six months ending June 30, 2026 (fiscal Q2 2026), Greenwich LifeSciences reported a net loss of $9.6 million, an increase from $6.5 million in the prior-year period. This rise in losses, driven by higher research and development and stock-based compensation expenses, led management to express "substantial doubt about the ability to continue as a going concern within one year" due to recurring losses and negative operating cash flows.

    2. Share Dilution from At-The-Market Offerings. The company continued to rely on At-The-Market (ATM) equity offerings to fund its operations, leading to share dilution. During the first half of fiscal year 2026 (ending June 30, 2026), Greenwich LifeSciences issued 379,762 shares through ATM offerings, generating net proceeds of $9.3 million.

    3. Fiscal Q1 2026 Earnings Miss and Analyst Downgrades. Greenwich LifeSciences reported a fiscal Q1 2026 (ended March 31, 2026) earnings per share (EPS) of -$0.39, missing analysts' consensus estimate of -$0.35. This miss was accompanied by negative revisions from some analysts, including a downgrade from "hold" to "sell" by Wall Street Zen on June 6, 2026, and a reiterated "sell (d-)" rating from Weiss Ratings on May 15, 2026.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -26.9% change in GLSI stock from 4/30/2026 to 8/18/2026 was primarily driven by a -6.7% change in the company's Shares Outstanding (Mil).
    (LTM values as of)43020268182026Change
    Stock Price ($)23.6217.26-26.9%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)1415-6.7%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    4/30/2026 to 8/18/2026
    ReturnCorrelation
    GLSI-26.9% 
    Market (SPY)6.8%30.9%
    Sector (XLV)16.3%1.5%

    Fundamental Drivers

    The -42.6% change in GLSI stock from 1/31/2026 to 8/18/2026 was primarily driven by a -6.7% change in the company's Shares Outstanding (Mil).
    (LTM values as of)13120268182026Change
    Stock Price ($)30.0717.26-42.6%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)1415-6.7%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    1/31/2026 to 8/18/2026
    ReturnCorrelation
    GLSI-42.6% 
    Market (SPY)11.2%49.5%
    Sector (XLV)10.1%22.7%

    Fundamental Drivers

    The 57.8% change in GLSI stock from 7/31/2025 to 8/18/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)73120258182026Change
    Stock Price ($)10.9417.2657.8%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)1315-9.9%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    7/31/2025 to 8/18/2026
    ReturnCorrelation
    GLSI57.8% 
    Market (SPY)22.4%37.8%
    Sector (XLV)31.8%16.8%

    Fundamental Drivers

    The 87.6% change in GLSI stock from 7/31/2023 to 8/18/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)73120238182026Change
    Stock Price ($)9.2017.2687.6%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)1315-12.1%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    7/31/2023 to 8/18/2026
    ReturnCorrelation
    GLSI87.6% 
    Market (SPY)73.6%30.7%
    Sector (XLV)32.5%20.3%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    GLSI Return-33%-38%-31%7%87%-17%-52%
    Peers Return-7%32%41%-1%13%9%108%
    S&P 500 Return27%-19%24%23%16%13%106%

    Monthly Win Rates [3]
    GLSI Win Rate42%50%25%50%42%38% 
    Peers Win Rate42%67%58%50%83%62% 
    S&P 500 Win Rate75%42%67%75%67%50% 

    Max Drawdowns [4]
    GLSI Max Drawdown-59%-71%-63%-46%-43%-62% 
    Peers Max Drawdown-27%-19%-12%-23%-29%-15% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: VRTX, APMD, ATTO, BLSM, BRVE.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 8/18/2026 (YTD)

    How Low Can It Go

    EventGLSIS&P 500
    2025 US Tariff Shock
      % Loss-29.9%-18.8%
      % Gain to Breakeven42.6%23.1%
      Time to Breakeven259 days79 days
    2024 Yen Carry Trade Unwind
      % Loss-17.6%-7.8%
      % Gain to Breakeven21.4%8.5%
      Time to Breakeven497 days18 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-13.7%-9.5%
      % Gain to Breakeven15.8%10.5%
      Time to Breakeven11 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-49.1%-6.7%
      % Gain to Breakeven96.6%7.1%
      Time to Breakeven249 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-69.7%-24.5%
      % Gain to Breakeven230.5%32.4%
      Time to Breakeven1292 days427 days

    Compare to VRTX, APMD, ATTO, BLSM, BRVE

    In The Past

    Greenwich LifeSciences's stock fell -29.9% during the 2025 US Tariff Shock. Such a loss loss requires a 42.6% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventGLSIS&P 500
    2025 US Tariff Shock
      % Loss-29.9%-18.8%
      % Gain to Breakeven42.6%23.1%
      Time to Breakeven259 days79 days
    2023 SVB Regional Banking Crisis
      % Loss-49.1%-6.7%
      % Gain to Breakeven96.6%7.1%
      Time to Breakeven249 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-69.7%-24.5%
      % Gain to Breakeven230.5%32.4%
      Time to Breakeven1292 days427 days

    Compare to VRTX, APMD, ATTO, BLSM, BRVE

    In The Past

    Greenwich LifeSciences's stock fell -29.9% during the 2025 US Tariff Shock. Such a loss loss requires a 42.6% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Greenwich LifeSciences (GLSI)

    Greenwich LifeSciences (GLSI) is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. The company's core mission is to address breast cancer and other cancers that express the HER2/neu protein, aiming to provide novel treatment options in the oncology field.

    The company's lead product candidate is GP2, an immunotherapy designed to prevent the recurrence of breast cancer. GP2 has successfully completed a Phase IIb clinical trial, marking a significant milestone in its development. This immunotherapy is specifically intended for patients who have previously undergone surgery for breast cancer, with the goal of reducing the risk of the disease returning.

    Therefore, Greenwich LifeSciences primarily serves the market of breast cancer patients who have completed initial surgical treatment and are seeking advanced therapies to prevent recurrence. Its target customers are within the oncology sector, specifically the post-surgical patient population requiring preventative immunological treatments for HER2/neu-expressing cancers.

    AI Analysis | Feedback

    Here are 1-3 brief analogies to describe Greenwich LifeSciences (GLSI):

    • It's like a small, highly focused Genentech working on new immunotherapies for breast cancer.
    • Imagine a startup division of a major pharmaceutical like Merck or Roche, solely dedicated to developing immunotherapies for breast cancer.

    AI Analysis | Feedback

    • GP2: An immunotherapy drug candidate in Phase IIb clinical trials for preventing breast cancer recurrence.

    AI Analysis | Feedback

    Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidate, GP2, has completed Phase IIb clinical trials. At this stage of development, the company is primarily engaged in research, development, and clinical trials, rather than commercial sales of a product.

    Therefore, Greenwich LifeSciences (GLSI) does not currently have major customers in the traditional sense, as it is not yet selling a commercialized product to individuals or other companies. Its primary activities are focused on advancing its drug candidates through clinical trials and seeking regulatory approval, not on generating revenue from product sales.

    AI Analysis | Feedback

    Creative Peptides

    AI Analysis | Feedback

    Snehal S. Patel, Chief Executive Officer, Chief Financial Officer, and Director
    Mr. Patel possesses over 30 years of experience in executive management, corporate development, operations, and investment banking within the healthcare industry. He has provided consulting, management, and advisory services for R&D and manufacturing design, scale-up, and operations at numerous public and private biotech companies, focusing on clinical and pre-clinical assets in areas such as stem cell therapy, multiple sclerosis t-cell therapy, oncolytic viruses, and disposable biotech manufacturing equipment. Prior to his current role, he served as an investment banker at Sanders Morris Harris, Ferghana Partners, and JP Morgan Chase, where his work centered on healthcare and biotech financing and strategic transactions. He also worked in operations and business development at consulting firms and at Bayer Corporation, specifically in the biotechnology division on the commercialization of recombinant Factor VIII and in Corporate Development involving licensing and M&A transactions. Mr. Patel frequently acquires company stock, indicating his confidence in Greenwich LifeSciences' future prospects.

    F. Joseph Daugherty, M.D., Chief Medical Officer and Director
    Dr. Daugherty brings over 35 years of experience in managing and overseeing biotechnology and biomedical projects. He is currently the Managing Partner of Phenolics, LLC and PharmaPrint, LLC, which are nutraceutical companies, and serves on the boards of several startup companies and a charitable foundation. Dr. Daugherty previously held positions as President, Chief Executive Officer, Chief Medical Officer, and Chairman of the board of directors at Eleos, Inc., a private, clinical-stage biotech company focused on anti-sense technology in cancer.

    Jaye Thompson, M.S., Ph.D., Vice President, Clinical and Regulatory Affairs
    Dr. Thompson holds the crucial role of Vice President, Clinical and Regulatory Affairs for Greenwich LifeSciences.

    David B. McWilliams, Chairman of the Board
    Mr. McWilliams has more than 40 years of experience in establishing biopharmaceutical and healthcare companies. He currently serves as the Chairman of the board of directors of BioHouston, Inc., an organization dedicated to advocating for Houston's life sciences industry. Mr. McWilliams has acted as a consultant and advisor at various levels for multiple private start-up biotech companies, assisting in the development of pre-clinical and clinical assets for cancer and other therapeutic areas. He was formerly the Chief Executive Officer of Greenwich LifeSciences. His career also includes roles as President of Harleco Diagnostics Division (EM Industries), General Manager and Program Manager of Abbott Laboratories, and Management Consultant at McKinsey & Company. He also served as Chief Executive Officer and President of Kallestad Diagnostics (Erbamont).

    AI Analysis | Feedback

    The key risks to Greenwich LifeSciences (GLSI) are primarily associated with its stage of development as a clinical-stage biopharmaceutical company focused on a single lead product. *

    Clinical Trial and Regulatory Risk

    Greenwich LifeSciences' success is heavily dependent on the successful completion of clinical trials and subsequent regulatory approval for its lead product candidate, GP2 (also referred to as GLSI-100), an immunotherapy for breast cancer. GP2 is currently in a Phase III clinical trial (FLAMINGO-01). Despite positive preliminary safety data from earlier phases and the ongoing Phase III trial, and the FDA's Fast Track designation, there is no guarantee of successful trial outcomes or market approval. Biopharmaceutical product development inherently carries a significant risk of failure at various stages of clinical trials, and regulatory requirements can be stringent and subject to change, potentially leading to delays or outright rejection. Manufacturing and pharmacy process concerns have also posed regulatory challenges in the past, though these have been addressed. *

    Financial Risk and Capital Constraints

    As a clinical-stage company, Greenwich LifeSciences has a history of substantial losses and does not generate revenue from product sales, anticipating continued losses as it advances GP2 through development and towards commercialization. The company requires significant additional financing to fund its operations and complete the development and potential commercialization of its product candidate. Its existing cash reserves are expected to fund operations for a limited period, necessitating ongoing efforts to raise capital. The reliance on "at-the-market" share sales for funding can lead to shareholder dilution, and a failure to secure adequate additional funds could force the company to delay or reduce its development programs. *

    Concentration Risk

    The company's business is highly concentrated on a single immunotherapy, GP2 (GLSI-100), as its primary product candidate. While Greenwich LifeSciences is exploring follow-on indications to expand the patient population and target other HER2/neu-expressing cancers, the entire pipeline strategy revolves around this single asset. This singular focus means that any setback, delay, or failure related to GP2 would have a severe and potentially catastrophic impact on the company's financial performance and future viability.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    ```html

    Greenwich LifeSciences' lead product candidate, GP2, an immunotherapy focused on preventing breast cancer recurrences in patients who have previously undergone surgery, targets HER2/neu-expressing cancers. The addressable markets for products and services related to breast cancer, particularly HER2-positive and HER2-low cancers, and cancer immunotherapies, are substantial.

    • The global breast cancer therapeutics market was estimated at USD 31.5 billion in 2024 and is projected to reach USD 71.3 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 8.5%. Another estimate places the global breast cancer market size at USD 26.23 billion in 2025, expected to grow to USD 38.54 billion by 2034 with a CAGR of 4.37%.
    • The global HER2-positive breast cancer treatment market is estimated at USD 11.38 billion in 2026 and is projected to reach USD 13.79 billion by 2031, with a CAGR of 3.92%. North America accounted for 41.52% of this market's revenue in 2025.
    • The global HER2 inhibitors market was valued at approximately USD 8.36 billion in 2025 and is expected to increase to approximately USD 13.69 billion by 2032, growing at a CAGR of 7.3%.
    • The global cancer immunotherapy market was valued at USD 136.39 billion in 2025 and is projected to reach approximately USD 367.63 billion by 2035, growing at a CAGR of 10.42%. Within this, the breast cancer segment is anticipated to show significant growth.
    • For HER2-low cancers, which GP2 also addresses (HER2 1-2+ patients), the market size across the 7 major markets (7MM) was approximately USD 3.2 billion in 2024. This market is projected to grow to USD 8.997 billion by 2034 in leading countries (US, EU4, UK, and Japan), at a CAGR of 11%. The United States market for HER2-low cancers was approximately USD 1.6 billion in 2024.
    ```

    AI Analysis | Feedback

    The future revenue growth for Greenwich LifeSciences (GLSI) over the next 2-3 years is primarily driven by the advancement and potential commercialization of its lead product candidate, GP2 (GLSI-100), an immunotherapy aimed at preventing breast cancer recurrences.

    1. Successful Completion and Positive Data from the Phase III FLAMINGO-01 Clinical Trial: The ongoing global Phase III FLAMINGO-01 clinical trial evaluating GLSI-100 is a critical driver. The company expects to report topline efficacy and safety data once a prespecified number of recurrence events occurs, with a projected timeframe of 12 to 18 months, depending on event rates. Preliminary data from the non-HLA-A*02 arm of the trial have shown an approximately 80% reduction in recurrence rate after the primary immunization series. Positive outcomes from this trial are essential for subsequent regulatory submissions and potential market entry.
    2. Regulatory Approvals for GP2 (GLSI-100): The company is actively progressing toward filing a Biological License Application (BLA) with the FDA in the US and pursuing regulatory filings with European Medicines Agency (EMA) in Europe. The FDA's approval of the first commercially manufactured lot of GP2 vials for use in the Phase III trial has significantly de-risked the future BLA filing process from a manufacturing perspective. If approved, GLSI-100 could be granted up to 12 years of market exclusivity under current law.
    3. Commercial Manufacturing and Supply Chain Readiness: Greenwich LifeSciences has made substantial progress in establishing its commercial manufacturing capabilities. The company manufactured the first three commercial lots of GP2 active ingredient in 2023, capable of producing approximately 200,000 doses, and the first commercial lot of finished GP2 vials in 2024. This readiness in manufacturing and supply chain is crucial for a timely and efficient market launch following regulatory approval.
    4. Market Penetration Addressing Unmet Medical Need: Upon potential approval, GP2 is positioned to address a significant unmet need in preventing breast cancer recurrences, particularly in patients who do not adequately respond to existing treatments like Herceptin or Kadcyla. There are approximately 700,000 new breast cancer patients and 9.5 million breast cancer survivors in the US and EU in 2025. Successful market penetration within this patient population would be a key driver of revenue growth.

    AI Analysis | Feedback

    Share Repurchases

    • Greenwich LifeSciences suspended its share repurchase program in July 2022.
    • Prior to suspension, the company repurchased approximately 520,000 shares of common stock for an aggregate of about $7.5 million.

    Share Issuance

    • Between January 1, 2024, and September 30, 2024, Greenwich LifeSciences raised approximately $1.75 million through an At-The-Market (ATM) agreement and nearly $2.5 million through a private placement offering.
    • In the first three weeks of January 2026, the company raised approximately $7 million via its ATM financing vehicle.
    • Cash burn in 2024 was offset in part through the sale of common stock via an ATM program and a private placement. The company also sold $1.2 million worth of shares in the ATM arrangement between January 1 and April 11, 2025.

    Capital Expenditures

    • Greenwich LifeSciences reported minimal to no significant capital expenditures on physical assets, with recent financial snapshots listing Capital Expenditures as $0.0.
    • The primary focus of capital utilization is on research and development, particularly funding for its Phase III FLAMINGO-01 clinical trial.
    • Research and development expenses increased to $2,292,040 for the three months ended September 30, 2024, up from $2,158,167 in the same quarter the previous year, mainly due to increased clinical expenses.

    Peer Outperformance in Biotechnology

    GLSI has outperformed 60% of its 364 Biotechnology peers over 5Y. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
    Share of Biotechnology constituents that GLSI has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    63%
    of 460 industry peers · 43.7% return
    3Y
    75%
    of 406 industry peers · 80.5% return
    5Y
    60%
    of 364 industry peers · -55.3% return
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is GLSI's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 7 9.7%79.7%140.2% CAH 411% · MCK 348% · COR 179%
    Health Care Services 20 20.0%41.9%9.5% HIMS 302% · RDNT 143% · DGX 72%
    Managed Health Care 8 33.2%-3.6%1.3% OSCR 142% · HQY 64% · ELV 14%
    Health Care Facilities 24 11.9%-3.3%-15.7% THC 289% · NHC 263% · ENSG 132%
    Health Care Equipment 51 -2.3%-9.2%-18.9% POCI 10738% · UFPT 396% · GKOS 288%
    Health Care Supplies 12 38.3%-12.4%-27.5% LNTH 314% · HAE 81% · MMSI 31%
    Pharmaceuticals 63 3.1%-1.7%-31.9% LQDA 2959% · INDV 1388% · ETON 1385%
    Life Sciences Tools & Services 108 -8.4%-32.7%-70.6% SNWV 1953% · ELMD 259% · MEDP 235%
    Health Care Technology 20 -28.4%-53.8%-73.9% SPOK 37% · HSTM -2% · VEEV -24%
    Biotechnology ← 365 6.6%-27.4%-77.2% BRTX 106400% · DNTH 1803% · CELZ 1443%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Recent Active Movers

    Top Gainers

    TickerCompanyCategory1W RtnYTD Rtn
    XLEState Street Energy Select Sector SPD...Equity4.5%43.4%
    XOPState Street SPDR S&P Oil & Gas Explo...Equity3.9%47.4%
    FXNFirst Trust Energy AlphaDEX FundEquity2.7%42.4%
    USOUnited States Oil Fund LPCommodity2.4%88.9%
    HGERHarbor Commodity All-Weather Strategy...Commodity2.2%37.9%
    IBBiShares Biotechnology ETFEquity1.9%20.7%
    IBITiShares Bitcoin Trust ETFCryptocurrency1.8%-26.3%
    ETHAiShares Ethereum Trust ETFCryptocurrency1.8%-35.6%
    FBTCFidelity Wise Origin Bitcoin FundCryptocurrency1.8%-26.2%
    COMTiShares GSCI Commodity Dynamic Roll S...Commodity1.8%37.5%

    Top Losers

    TickerCompanyCategory1W RtnYTD Rtn
    PALLETFS Physical Palladium SharesCommodity-5.6%-19.6%
    KWEBKraneShares CSI China Internet ETFEquity-4.7%-21.4%
    URAGlobal X Uranium ETFEquity-3.4%2.1%
    XLBState Street Materials Select Sector ...Equity-2.7%14.7%
    ROBOROBO Global Robotics & Automation Ind...Equity-2.6%18.0%
    ICLNiShares Global Clean Energy ETFEquity-2.5%8.0%
    MAGSRoundhill Magnificent Seven ETFEquity-2.5%1.2%
    BOTZGlobal X Funds Global X Robotics & Ar...Equity-2.5%0.9%
    XLYState Street Consumer Discretionary S...Equity-2.4%-2.4%
    IYMiShares U.S. Basic Materials ETFEquity-2.0%21.4%

    Top Gainers

    TickerCompanyCategory1M RtnYTD Rtn
    RINGiShares MSCI Global Gold Miners ETFEquity28.3%5.5%
    NASATema Space Innovators ETFEquity14.1%2.0%
    URAGlobal X Uranium ETFEquity12.8%2.1%
    SLViShares Silver TrustCommodity12.7%-10.8%
    MISLFirst Trust Indxx Aerospace & Defense...Equity12.6%11.1%
    ARKXARK Space & Defense Innovation ETFEquity11.5%-2.6%
    LITGlobal X Lithium & Battery Tech ETFEquity10.6%14.1%
    ITAiShares U.S. Aerospace & Defense ETFEquity10.0%17.5%
    XLEState Street Energy Select Sector SPD...Equity9.9%43.4%
    GDEWisdomTree Efficient Gold Plus Equity...Equity9.9%-5.1%

    Top Losers

    TickerCompanyCategory1M RtnYTD Rtn
    EWZiShares MSCI Brazil ETFEquity-5.0%6.1%
    EDVVanguard World Funds Extended Duratio...Bond-4.2%-7.1%
    ILFiShares Latin America 40 ETFEquity-2.9%9.1%
    USRTiShares Core U.S. REIT ETFReal Estate-2.8%17.4%
    SCHHSchwab U.S. REIT ETFReal Estate-2.7%14.7%
    TLTiShares 20+ Year Treasury Bond ETFBond-2.7%-4.2%
    KWEBKraneShares CSI China Internet ETFEquity-2.4%-21.4%
    IYTiShares U.S. Transportation ETFEquity-2.4%16.1%
    SPTLState Street SPDR Portfolio Long Term...Bond-2.3%-3.7%
    SPLBState Street SPDR Portfolio Long Term...Bond-2.3%-3.3%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    GLSIVRTXAPMDATTOBLSMBRVEMedian
    NameGreenwic.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Mkt Price17.26528.1931.8123.2416.1026.7524.99
    Mkt Cap0.3134.0----67.1
    Rev LTM012,587----6,294
    Op Inc LTM-224,777----2,377
    FCF LTM-123,796----1,892
    FCF 3Y Avg-91,957----974
    CFO LTM-124,293----2,140
    CFO 3Y Avg-92,398----1,195

    Growth & Margins

    GLSIVRTXAPMDATTOBLSMBRVEMedian
    NameGreenwic.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Rev Chg LTM-10.2%----10.2%
    Rev Chg 3Y Avg-9.8%----9.8%
    Rev Chg Q-12.5%----12.5%
    QoQ Delta Rev Chg LTM-3.0%----3.0%
    Op Inc Chg LTM-15.2%2,497.9%----1,241.3%
    Op Inc Chg 3Y Avg-36.3%792.2%----378.0%
    Op Mgn LTM-37.9%----37.9%
    Op Mgn 3Y Avg-23.9%----23.9%
    QoQ Delta Op Mgn LTM--0.2%-----0.2%
    CFO/Rev LTM-34.1%----34.1%
    CFO/Rev 3Y Avg-19.6%----19.6%
    FCF/Rev LTM-30.2%----30.2%
    FCF/Rev 3Y Avg-15.7%----15.7%

    Valuation

    GLSIVRTXAPMDATTOBLSMBRVEMedian
    NameGreenwic.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Mkt Cap0.3134.0----67.1
    P/S-10.6----10.6
    P/Op Inc-11.528.1----8.3
    P/EBIT-11.526.6----7.5
    P/E-11.630.4----9.4
    P/CFO-20.231.2----5.5
    Total Yield-8.6%3.3%-----2.7%
    Dividend Yield0.0%0.0%----0.0%
    FCF Yield 3Y Avg-4.6%1.6%-----1.5%
    D/E0.00.0----0.0
    Net D/E-0.0-0.0-----0.0

    Returns

    GLSIVRTXAPMDATTOBLSMBRVEMedian
    NameGreenwic.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    1M Rtn5.8%8.8%27.2%6.1%0.6%-10.2%5.9%
    3M Rtn-34.4%21.6%27.2%6.1%0.6%-10.2%3.4%
    6M Rtn-31.6%10.7%27.2%6.1%0.6%-10.2%3.4%
    12M Rtn43.7%35.5%27.2%6.1%0.6%-10.2%16.7%
    3Y Rtn80.5%53.2%27.2%6.1%0.6%-10.2%16.7%
    1M Excs Rtn19.3%6.6%23.9%2.8%-2.7%-13.6%4.7%
    3M Excs Rtn-39.7%17.1%23.3%2.2%-3.3%-14.1%-0.5%
    6M Excs Rtn-44.0%-1.7%14.8%-6.3%-11.8%-22.6%-9.0%
    12M Excs Rtn22.6%15.2%8.0%-13.1%-18.6%-29.5%-2.6%
    3Y Excs Rtn-8.9%-21.3%-45.1%-66.2%-71.7%-82.5%-55.6%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/11/20266/4/20266/1/202611/14/20258/14/20255/20/20254/15/202511/14/20248/14/20245/20/20244/15/202410/19/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-4-6-8-4-4-3-10-3-3-3-3-3
    Operating Income-4-6-8-4-4-3-10-3-3-3-3-3
    Net Income-4-6-8-4-4-3-10-3-3-2-3-2
    EPS-0.27-0.39-0.58-0.30-0.28-0.21-0.74-0.20-0.20-0.19-0.21-0.19
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-22-22-19-20-19-18-18-11-11-10-9-9
    Operating Income TTM-22-22-19-20-19-18-18-11-11-10-9-9
    Net Income TTM-22-21-19-20-19-18-17-10-10-9-9-9
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth-6.7%-106.9%18.2%-53.0%-41.6%-9.1%-242.4%-9.0%-52.3%-13.2%2.0%-5.0%
    Operating Income Growth-6.7%-106.8%18.2%-53.0%-41.6%-9.1%-242.4%-9.0%-52.3%-13.2%2.0%-5.0%
    Net Income Growth-5.3%-106.1%18.0%-55.6%-43.8%-11.0%-251.9%-11.6%-60.1%-16.4%1.6%-3.1%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash9116433467679
    Total Debt000000000000
    Net Debt / (Cash)-9-11-6-4-3-3-4-6-7-6-7-9
    Cash Flows Quarterly            
    FCF from Operations-2-5-3-3-2-2-2-3-1-2-2-2
    Cash Flows TTM            
    FCF from Operations TTM-12-13-10-9-9-7-7-8-7-7-6-6
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-17.7%-26.2%-39.1%-22.0%-21.0%-16.3%-60.1%-19.1%-19.7%-19.3%-22.7%-21.2%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-24.0%-24.7%-22.9%-26.9%-26.4%-26.3%-27.3%-18.8%-19.5%-18.3%-18.6%-19.8%

    Segment Financials

    Revenue by Segment
    $ Mil2025202420232022
    Clinical development programs0000
    Total0000


    Assets by Segment
    $ Mil20252024202320222021
    Clinical development programs6471327
    Total6471327


    Price Behavior

    Price Behavior
    Market Price$17.26 
    Market Cap ($ Bil)0.3 
    First Trading Date09/25/2020 
    Distance from 52W High-48.6% 
       50 Days200 Days
    DMA Price$18.23$20.56
    DMA Trendupdown
    Distance from DMA-5.3%-16.0%
     3M1YR
    Volatility97.7%99.0%
    Downside Capture287.51314.34
    Upside Capture45.17292.52
    Correlation (SPY)32.7%38.1%
    GLSI Betas & Captures as of 7/31/2026

     1M2M3M6M1Y3Y
    Beta4.322.492.263.452.941.57
    Up Beta3.305.785.334.803.141.36
    Down Beta-0.69-0.250.491.872.311.19
    Up Capture223%33%43%324%829%900%
    Bmk +ve Days11223567138427
    Stock +ve Days10203259122358
    Down Capture801%344%282%257%181%111%
    Bmk -ve Days11212859114326
    Stock -ve Days12223066129388

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with GLSI
    GLSI42.0%98.8%0.80-
    Sector ETF (XLV)26.3%15.5%1.3116.8%
    Equity (SPY)20.4%12.8%1.1738.0%
    Gold (GLD)29.8%28.5%0.915.4%
    Commodities (DBC)40.2%20.2%1.56-14.9%
    Real Estate (VNQ)13.1%13.9%0.6510.8%
    Bitcoin (BTCUSD)-45.4%42.7%-1.3026.9%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with GLSI
    GLSI-16.6%80.1%0.12-
    Sector ETF (XLV)6.6%15.0%0.2519.8%
    Equity (SPY)13.1%17.2%0.5928.6%
    Gold (GLD)19.8%18.6%0.874.3%
    Commodities (DBC)9.8%19.6%0.39-3.9%
    Real Estate (VNQ)2.4%18.9%0.0219.1%
    Bitcoin (BTCUSD)7.1%52.6%0.3217.7%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with GLSI
    GLSI13.0%421.7%0.44-
    Sector ETF (XLV)10.4%16.7%0.512.5%
    Equity (SPY)15.2%17.9%0.722.9%
    Gold (GLD)12.1%16.2%0.61-3.5%
    Commodities (DBC)7.8%18.1%0.35-0.5%
    Real Estate (VNQ)4.8%20.7%0.202.1%
    Bitcoin (BTCUSD)59.9%66.0%1.003.6%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date7312026
    Short Interest: Shares Quantity1.5 Mil
    Short Interest: % Change Since 71520265.0%
    Average Daily Volume0.2 Mil
    Days-to-Cover Short Interest7.2 days
    Basic Shares Quantity14.6 Mil
    Short % of Basic Shares10.5%

    Earnings Returns History

    Updated 6/3/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    SUMMARY STATS   
    # Positive000
    # Negative000
    Median Positive   
    Median Negative   
    Max Positive   
    Max Negative   
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    SUMMARY STATS   
    # Positive000
    # Negative000
    Median Positive   
    Median Negative   
    Max Positive   
    Max Negative   

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/11/202610-Q
    03/31/202606/04/202610-Q
    12/31/202506/01/202610-K
    09/30/202511/14/202510-Q
    06/30/202508/14/202510-Q
    03/31/202505/20/202510-Q
    12/31/202404/15/202510-K
    09/30/202411/14/202410-Q
    06/30/202408/14/202410-Q
    03/31/202405/20/202410-Q
    12/31/202304/15/202410-K
    09/30/202310/19/202310-Q
    06/30/202308/21/202310-Q
    03/31/202305/22/202310-Q
    12/31/202203/31/202310-K
    09/30/202211/14/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/11/202610-Q
    03/31/202606/04/202610-Q
    12/31/202506/01/202610-K
    09/30/202511/14/202510-Q
    06/30/202508/14/202510-Q
    03/31/202505/20/202510-Q
    12/31/202404/15/202510-K
    09/30/202411/14/202410-Q
    06/30/202408/14/202410-Q
    03/31/202405/20/202410-Q
    12/31/202304/15/202410-K
    09/30/202310/19/202310-Q
    06/30/202308/21/202310-Q
    03/31/202305/22/202310-Q
    12/31/202203/31/202310-K
    09/30/202211/14/202210-Q
    06/30/202208/15/202210-Q
    03/31/202205/20/202210-Q
    12/31/202103/21/202210-K
    09/30/202111/15/202110-Q
    06/30/202108/13/202110-Q
    03/31/202105/20/202110-Q
    12/31/202003/31/202110-K
    09/30/202011/16/202010-Q
    06/30/202009/28/2020424B4

    Insider Activity

    Updated 7/29/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Patel, SnehalCEO and CFODirectBuy729202613.621,50020,43076,397,331Form
    2Patel, SnehalCEO and CFODirectBuy727202612.881,10014,16872,227,202Form
    3Patel, SnehalCEO and CFODirectBuy727202613.142,50032,85073,670,750Form
    4Patel, SnehalCEO and CFODirectBuy114202627.542,90079,866154,287,397Form
    5Patel, SnehalCEO and CFODirectBuy105202621.364,30091,848119,603,227Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Patel, SnehalCEO and CFODirectBuy729202613.621,50020,43076,397,331Form
    2Patel, SnehalCEO and CFODirectBuy727202612.881,10014,16872,227,202Form
    3Patel, SnehalCEO and CFODirectBuy727202613.142,50032,85073,670,750Form
    4Patel, SnehalCEO and CFODirectBuy114202627.542,90079,866154,287,397Form
    5Patel, SnehalCEO and CFODirectBuy105202621.364,30091,848119,603,227Form
    6Patel, SnehalCEO and CFODirectBuy102202621.732,90063,017121,581,566Form
    7Patel, SnehalCEO and CFODirectBuy1219202512.624,10051,74270,573,589Form
    8Patel, SnehalCEO and CFODirectBuy112820258.374,60038,50246,772,414Form
    9Patel, SnehalCEO and CFODirectBuy111220258.4310,60089,35847,068,922Form
    10Patel, SnehalCEO and CFODirectBuy110420259.262,30021,29851,605,073Form

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 8/18/2026